Hanna Burkhalter

Dr. Hanna Burkhalter

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2014 in Transplant International
Verified
Journal Article
Closed access
PDF file
SGSabina M De Geest
Sabina M De Geest
HBHanna Burkhalter
Hanna Burkhalter
LBLaura Bogert
Laura Bogert
LBLut Berben
Lut Berben
TGTracy R. Glass
Tracy R. Glass
TSthe Psychosocial Interest Group and Swiss Transplant Cohort Study
the Psychosocial Interest Group and Swiss Transplant Cohort Study
Although medication nonadherence (MNA) is a major risk factor for poor outcomes, the evolution of MNA from pre- to 3 years post-transplant among the four major organ transplant groups remains unknown. Therefore, this study described this evolution and investigated whether pretransplant MNA predicts post-transplant immunosuppressive medication nonadherence (IMNA). Adult participants (single transplant, pretransplant and ≤1 post-transplant assessment, using medications pretransplant) in the Swiss Transplant Cohort Study (a prospective nation-wide cohort study) were included. Nonadherence, defined as any deviation from dosing schedule, was assessed using two self-report questions pretransplant and at 6, 12, 24 and 36 months post-transplant. Nonadherence patterns were modelled using generalized estimating equations. The sample included 1505 patients (average age: 52.5 years (SD: 13.1); 36.3% females; 924 renal, 274 liver, 181 lung, 126 heart). The magnitude and variability of self-reported MNA decreased significantly from pretransplant to 6 months post-transplant (OR = 0.21; 95% CI: 0.16-0.27). Post-transplant IMNA increased continuously from 6 months to 3 years post-transplant (OR = 2.75; 95% CI: 1.97-3.85). Pretransplant MNA was associated with threefold higher odds of post-transplant IMNA (OR = 3.10; 95% CI: 2.29-4.21). As pretransplant MNA predicted post-transplant IMNA and a continuous increase in post-transplant IMNA was observed, early adherence-supporting interventions are indispensible.

13 October 2010 in Sleep and Biological Rhythms
Verified
Journal Article
Closed access
PDF file
HBHanna Burkhalter
Hanna Burkhalter
SSSusan M Sereika
Susan M Sereika
SESandra Engberg
Sandra Engberg
AWAnna Wirz-Justice
Anna Wirz-Justice
JSJürg Steiger
Jürg Steiger
SGSabina M De Geest
Sabina M De Geest

2 September 2014 in Transplant International
Verified
Journal Article
Open access
PDF file
HBHanna Burkhalter
Hanna Burkhalter
AWAnna Wirz-Justice
Anna Wirz-Justice
KDKris Denhaerynck
Kris Denhaerynck
TFThomas Fehr
Thomas Fehr
JSJürg Steiger
Jürg Steiger
SGSabina M De Geest
Sabina M De Geest
This study assessed the effect and feasibility of morning bright light therapy (BLT) on sleep, circadian rhythms, subjective feelings, depressive symptomatology and cognition in renal transplant recipients (RTx) diagnosed with sleep–wake disturbances (SWD). This pilot randomized multicentre wait‐list controlled trial included 30 home‐dwelling RTx randomly assigned 1:1 to either 3 weeks of BLT or a wait‐list control group. Morning BLT (10 000 lux) was individually scheduled for 30 min daily for 3 weeks. Wrist actimetry (measuring sleep and circadian rhythms), validated instruments (subjective feelings and cognition) and melatonin assay (circadian timing) were used. Data were analysed via a random‐intercept regression model. Of 30 RTx recipients (aged 58 ± 15, transplanted 15 ± 6 years ago), 26 completed the study. While BLT had no significant effect on circadian and sleep measures, sleep timing improved significantly. The intervention group showed a significant get‐up time phase advance from baseline to intervention (+24 min) [(standardized estimates (SE): −0.23 (−0.42; −0.03)] and a small (+14 min) but significant bedtime phase advance from intervention to follow‐up (SE: −0.25 (−0.41; −0.09). Improvement in subjective feelings and depressive symptomatology was observed but was not statistically significant. Bright light therapy showed preliminary indications of a beneficial effect in RTx with sleep–wake disturbances. (ClinicalTrials.gov number: NCT01256983)

10 October 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
HBHanna Burkhalter
Hanna Burkhalter
DBDaniel P Brunner
Daniel P Brunner
AWAnna Wirz-Justice
Anna Wirz-Justice
Christian CajochenChristian Cajochen
Christian Cajochen
TWTerri E. Weaver
Terri E. Weaver
SGSabina M De Geest
Sabina M De Geest
Background: Poor sleep quality (SQ) and daytime sleepiness (DS) are common in renal transplant (RTx) recipients; however, related data are rare. This study describes the prevalence and frequency of self-reported sleep disturbances in RTx recipients. Methods: This cross-sectional study included 249 RTx recipients transplanted at three Swiss transplant centers. All had reported poor SQ and / or DS in a previous study. With the Survey of Sleep (SOS) self-report questionnaire, we screened for sleep and health habits, sleep history, main sleep problems and sleep-related disturbances. To determine a basis for preliminary sleep diagnoses according to the International Classification of Sleep Disorders (ICSD), 164 subjects were interviewed (48 in person, 116 via telephone and 85 refused). Descriptive statistics were used to analyze the data and to determine the frequencies and prevalences of specific sleep disorders. Results: The sample had a mean age of 59.1 ± 11.6 years (60.2% male); mean time since Tx was 11.1 ± 7.0 years. The most frequent sleep problem was difficulty staying asleep (49.4%), followed by problems falling asleep (32.1%). The most prevalent sleep disturbance was the need to urinate (62.9%), and 27% reported reduced daytime functionality. Interview data showed that most suffered from the first ICSD category: insomnias. Conclusion: Though often disregarded in RTx recipients, sleep is an essential factor of wellbeing. Our findings show high prevalences and incidences of insomnias, with negative impacts on daytime functionality. This indicates a need for further research on the clinical consequences of sleep disturbances and the benefits of insomnia treatment in RTx recipients.

11 December 2013 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
HBHanna Burkhalter
Hanna Burkhalter
AWAnna Wirz‐Justice
Anna Wirz‐Justice
CCChristian Cajochen
Christian Cajochen
TWTerri E. Weaver
Terri E. Weaver
JSJürg Steiger
Jürg Steiger
SGSabina M De Geest
Sabina M De Geest

1 September 2013 in Progress in Transplantation
Verified
Journal Article
Closed access
SGSabina M De Geest
Sabina M De Geest
HBHanna Burkhalter
Hanna Burkhalter
LBLut Berben
Lut Berben
LBLaura Jane Bogert
Laura Jane Bogert
KDKris Denhaerynck
Kris Denhaerynck
FSFor the Psychosocial Interest, Group, Swiss Transplantm, Cohort Study
For the Psychosocial Interest, Group, Swiss Transplantm, Cohort Study
Background: Understanding outcomes after transplant requires a biopsychosocial model that includes biomedical and psychosocial factors. The latter, to date, are assessed only in a limited way as part of transplant registries or cohort studies. The Swiss Transplant Cohort Study (STCS) is a nationwide open cohort study (starting May 2008) to systematically and prospectively assess psychosocial factors. This article describes the framework underpinning STCS's psychosocial assessment. Methods: The STCS framework was adapted from the multidimensional conceptual perspective of Dew et al to describe transplant psychosocial domains and specific outcomes by adding a time perspective, a system perspective, and interaction among domains. Results: We propose a multidimensional, multilevel biopsychosocial framework representing mutually influencing domains from before to after transplant, and exemplify each domain by factors included in STCS and their measurement. The transplant patient, centrally positioned, is described by clinical and sociodemographic characteristics (eg, socioeconomic status, educational, professional, and relationship status). The following psychosocial domains further describe the patient: (1) physical/functional (eg, perceived health status, sleep quality, daytime sleepiness), (2) psychological (eg, depression, stress), (3) behavioral (eg, medication adherence, smoking, drug use, physical activity, sun protection), (4) social (eg, work capacity/return to work), and (5) global quality of life. Factors associated with health care system level (eg, trust in transplant team) are also included in the model. Conclusion: The STCS's psychosocial framework provides a basis for studying the interplay of biomedical, sociodemographic, psychosocial, behavioral, and health care system factors in view of transplant outcomes and therefore has the potential to guide biopsychosocial transplant research.